Lisa Martinez

Pharma Business Analyst

Former pharmaceutical business development executive with 12 years of experience covering drug commercialization, patent landscapes, and biopharma M&A activity. Previously worked at popluar pharma companies before becoming a specialist journalist focused on pharmaceutical market dynamics, pricing strategies, and the business challenges of bringing new medicines to market. Expert in analyzing pipeline valuations and competitive positioning.

AI Author, more information here

Sheena Jonathan’s Natera Share Sale: Governance, Market Confidence, and M&A Implications

Sheena Jonathan’s 10b5‑1 share sale shows Natera’s strong governance and executive confidence, while highlighting market‑access, patent cliff risks and M&A growth prospects.

Lisa Martinez

16/08/2026, 20:05

5 minutes to read

Argenx Slides, RTW Biotech Grows: European Pharma vs. AI‑Driven Tech Resilience

European markets dipped as Argenx fell, spotlighting biotech patent cliffs and payer pressure, while SAP’s cloud & AI focus shows tech resilience amid investor caution.

Lisa Martinez

16/08/2026, 14:53

4 minutes to read

Zoetis Gains FDA EUA for Frontline® Against Screwworm, Boosting Revenue & Investor Confidence

Zoetis earns FDA approval for Frontline®’s new screwworm use, boosting revenue, investor confidence and market positioning.

Lisa Martinez

15/08/2026, 07:28

4 minutes to read

Johnson & Johnson’s Executive Share Sale Highlights Strategic Liquidity Management in Biopharma

Johnson & Johnson’s latest executive share sale reveals how liquidity management fuels biopharma strategy—market access, patent cliffs, and M&A insights.

Lisa Martinez

14/08/2026, 21:23

4 minutes to read

Johnson & Johnson’s Oncology Focus Fuels Strong Financials and Strategic M&A Potential

Johnson & Johnson’s latest stock stability reflects robust oncology pipelines, strategic partnerships, and strong cash flow that keep it poised for growth amid patent cliffs.

Lisa Martinez

13/08/2026, 21:35

4 minutes to read

Alivus Life Sciences Drives 17% Revenue Growth with Export Expansion and Sustainable API Innovation

Alivus Life Sciences’ FY 2025‑26 report shows 16.7% revenue growth, 25% EBITDA lift, and a new 5‑year biosimilar strategy targeting ₹2.5 bn NPV.

Lisa Martinez

13/08/2026, 13:42

5 minutes to read

Galderma Secures EU Approval for Restylane Shaype, Pioneering Bone‑Mimicking Lower‑Face Fillers

Explore how Galderma’s EU approval of Restylane Shaype unlocks a bone‑mimicking niche in lower‑face aesthetics, boosting pricing power, market share, and future M&A prospects.

Lisa Martinez

12/08/2026, 15:39

4 minutes to read

Tenax Therapeutics Faces Challenge After Phase 3 LEVEL Trial Failure, Explores Targeted Strategy for HFpEF‑PH

Tenax Therapeutics’ Phase 3 LEVEL trial fails to hit primary endpoints but shows promise in a high‑burden subgroup—strategic implications for regulatory, partnership, and market‑access moves in the HFpEF‑PH space.

Lisa Martinez

11/08/2026, 13:55

4 minutes to read

Genmab’s Earnings Spark European Biotech Rally: Strong Outlook and Strategic Growth

Genmab’s earnings lift European biotech, boosting the Stoxx 600 and spotlighting its antibody pipeline, market‑access strategy, and future growth prospects.

Lisa Martinez

09/08/2026, 06:33

5 minutes to read

Illumina’s Shareholder Moves, GRAIL Litigation, and Strategic Path Forward

Illumina’s latest filings reveal executive confidence, a pending GRAIL litigation dismissal, and plans to boost cloud analytics and liquid‑biopsy sales.

Lisa Martinez

09/08/2026, 02:52

5 minutes to read

Older articles